Clinical trial
An Open-Label Randomized Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of 2019 Novel Coronavirus Disease (COVID-19)
NCT04536090 is registered in ClinicalTrials.gov with Institut de Recherches Cliniques de Montreal as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Randomized Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of 2019 Novel Coronavirus Disease (COVID-19)
- Lead sponsor
- Institut de Recherches Cliniques de Montreal
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- January 31, 2022
- Completion date
- June 30, 2023
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.